Miromatrix Medical IncNASDAQ:MIRO
- LAST PRICE3.1200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.9500/ 1
- Ask / Lots4.0000/ 60
- Open / Previous Close3.2800 / 3.1200
- Day Range
- 52 Week Range
- Volume11,134
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MIRO |
|---|---|---|
| 09:32 ET | 638 | 3.28 |
| 09:57 ET | 100 | 3.34 |
| 10:08 ET | 100 | 3.3396 |
| 10:09 ET | 100 | 3.315 |
| 10:15 ET | 400 | 3.3 |
| 10:24 ET | 100 | 3.3 |
| 10:44 ET | 201 | 3.3 |
| 10:51 ET | 400 | 3.3 |
| 10:54 ET | 200 | 3.3 |
| 11:52 ET | 100 | 3.29 |
| 11:54 ET | 350 | 3.3 |
| 12:06 ET | 100 | 3.3 |
| 12:53 ET | 200 | 3.3 |
| 01:54 ET | 200 | 3.3 |
| 02:03 ET | 100 | 3.3 |
| 02:07 ET | 100 | 3.3 |
| 02:54 ET | 200 | 3.3 |
| 03:12 ET | 100 | 3.3 |
| 03:14 ET | 100 | 3.2801 |
| 03:15 ET | 400 | 3.28 |
| 03:17 ET | 700 | 3.27 |
| 03:19 ET | 100 | 3.2 |
| 03:21 ET | 497 | 3.21 |
| 03:26 ET | 100 | 3.2 |
| 03:28 ET | 200 | 3.2 |
| 03:30 ET | 453 | 3.17 |
| 03:37 ET | 100 | 3.17 |
| 03:44 ET | 202 | 3.15 |
| 03:48 ET | 100 | 3.15 |
| 03:50 ET | 300 | 3.15 |
| 03:53 ET | 100 | 3.17 |
| 03:55 ET | 725 | 3.15 |
| 03:57 ET | 145 | 3.07 |
| 04:00 ET | 589 | 3.12 |
Yesterday
Feb 6, 2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Miromatrix Medical Inc. - MIRO, from 11:03PM ET on Monday Feb 06, 2023 by PR Newswire
11:03PM ET on Monday Feb 06, 2023 by PR Newswire
Feb 4, 2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Miromatrix Medical Inc. - MIRO, from 11:30PM ET on Saturday Feb 04, 2023 by GlobeNewswire
11:30PM ET on Saturday Feb 04, 2023 by GlobeNewswire
Feb 2, 2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Miromatrix Medical Inc. - MIRO, from 8:26PM ET on Thursday Feb 02, 2023 by Newsfile
8:26PM ET on Thursday Feb 02, 2023 by Newsfile
Feb 1, 2023
Miromatrix, Baxter to Collaborate on Treatment Options for Acute Liver Failure, from 10:16AM ET on Wednesday Feb 01, 2023 by MT Newswires
10:16AM ET on Wednesday Feb 01, 2023 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Miromatrix Medical Inc | 65.2M | -2.3x | --- |
Immunome Inc | 64.9M | -1.7x | --- |
HCW Biologics Inc | 66.0M | -5.2x | --- |
Galera Therapeutics Inc | 64.4M | -1.0x | --- |
Aptose Biosciences Inc | 63.8M | -1.1x | --- |
Candel Therapeutics Inc | 66.7M | -5.5x | --- |
Company Information
Miromatrix Medical Inc. a life sciences company. The Company is engaged in providing the technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company’s technology platform uses a two-step method of decellularization and recellularization. Its development focus is on bioengineering livers and kidneys, and its technology platform is also applicable to bioengineering other organs, including hearts, lungs, and pancreases. Decellularization is a process that is designed to remove porcine cells from the organs obtained from pigs to create a purified acellular extracellular matrix (ECM). Its perfusion process purifies the organs while preserving the mechanical structures and vascular networks. Recellularization is a process that incorporates perfusion to re-seed the ECM with unmodified human cells inside individual bioreactors. The Company's product pipeline includes miroliver, mirokidney, miroheart, mirolung and miropancreas.
Contact Information
- Headquarters
- 6455 Flying Cloud Drive, Suite 107EDEN PRAIRIE, MN, United States 55344
- Phone
- 612-202-7026
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Buckman
- Chief Executive Officer, Director
- Jeffrey Ross
- Chief Financial Officer, Secretary
- James Douglas
- Vice President - Quality
- Laji Kattungal
- Vice President - Research & Development
- John Barry
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $65.2M |
|---|---|
Revenue (TTM) | $31.1K |
Shares Outstanding | 20.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.38 |
Book Value | $2.66 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | 2,095.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -92,039.49% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
